恒星集团(中国)

Akeso Secures $250 Million USD to Propel Global Expansion of Its Innovative Drug Pipeline

2024-10-13

Akeso Secures $250 Million USD to Propel Global Expansion of Its Innovative Drug Pipeline

Akeso's Cadonilimab Receives Second Indication Approval from NMPA for First-Line Treatment of Gastric/GEJ Cancer in All-Comers Population

2024-09-30

Akeso's Cadonilimab Receives Second Indication Approval from NMPA for First-Line Treatment of Gastric/GEJ Cancer in All-Comers Population

Akeso’s Ebronucimab（PCSK9) Approved for Two Indications for the Treatment of Hypercholesterolemia in China

2024-09-30

Akeso’s Ebronucimab（PCSK9) Approved for Two Indications for the Treatment of Hypercholesterolemia in China

ESMO 2024 | Akeso Published First-Ever Efficacy Data for PD-1/VEGF Bispecific Antibody Ivonescimab with or without CD47 Antibody plus FOLFOXIRI for mCRC

2024-09-18

ESMO 2024 | Akeso Published First-Ever Efficacy Data for PD-1/VEGF Bispecific Antibody Ivonescimab with or without CD47 Antibody plus FOLFOXIRI for mCRC

ESMO 2024 | Akeso’s Ivonescimab plus Chemo in First-Line Triple-negative Breast Cancer Showed Promising Preliminary Efficacy and Good Safety

2024-09-18

ESMO 2024 | Akeso’s Ivonescimab plus Chemo in First-Line Triple-negative Breast Cancer Showed Promising Preliminary Efficacy and Good Safety

ESMO 2024 | Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1–Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

2024-09-18

ESMO 2024 | Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1–Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

WCLC 2024 | Perioperative Ivonescimab (PD-1/VEGF) for NSCLC Demonstrated Clinically Significant Phase II Results, Presented in Oral Session

2024-09-09

WCLC 2024 | Perioperative Ivonescimab (PD-1/VEGF) for NSCLC Demonstrated Clinically Significant Phase II Results, Presented in Oral Session

WCLC 2024 | Akeso's Ivonescimab Head-to-Head Phase III Data Against Pembrolizumab Unveiled

2024-09-08

WCLC 2024 | Akeso's Ivonescimab Head-to-Head Phase III Data Against Pembrolizumab Unveiled

Akeso to Present Data from 13 Clinical Studies at ESMO 2024, Featuring its Internally Developed Cadonilimab, Ivonescimab, Ligufalimab, and other I/O Antibodies

2024-09-06

Akeso to Present Data from 13 Clinical Studies at ESMO 2024, Featuring its Internally Developed Cadonilimab, Ivonescimab, Ligufalimab, and other I/O Antibodies

Akeso's 2024 First Half Interim Results: Expanding Global Lead in IO Bispecific Antibodies, Advancing New Therapies, and Accelerating Commercialization

2024-08-29

Akeso's 2024 First Half Interim Results: Expanding Global Lead in IO Bispecific Antibodies, Advancing New Therapies, and Accelerating Commercialization

Ivonescimab (PD-1/VEGF) Received Priority Review from China’s NMPA for First-Line Treatment of PD-L1 Positive NSCLC

2024-08-15

Ivonescimab (PD-1/VEGF) Received Priority Review from China’s NMPA for First-Line Treatment of PD-L1 Positive NSCLC

Two Ivonescimab (PD-1/VEGF) Results including Phase 3 Monotherapy versus Pembrolizumab Monotherapy in First-Line Treatment for PD-L1 Positive NSCLC to Be Presented at WCLC 2024

2024-08-10

Two Ivonescimab (PD-1/VEGF) Results including Phase 3 Monotherapy versus Pembrolizumab Monotherapy in First-Line Treatment for PD-L1 Positive NSCLC to Be Presented at WCLC 2024

« 1 2 3 4 5 6 7 8 9 »